Business Wire

Mundipharma and Medical Developments International announce a new alliance for the commercialisation of Penthrox® in Europe

Del

Mundipharma International Corporation Limited (Mundipharma) and Medical Developments International Limited (ASX:MVP) today announced that they have entered into a License, Development and Commercialisation Agreement for Penthrox® (low dose methoxyflurane) in Europe, as a self-inhaled analgesic for the treatment of emergency pain.

Mundipharma will have exclusive product rights in 39 European markets including France, Germany, Italy and Spain, but excluding Hungary, Republic of Ireland and the United Kingdom. First country launches may begin in 2016 following registration and local pricing and reimbursement approvals.

Under the terms of the agreement, Mundipharma will pay MVP upfront and milestone payments of up to $54.5 million US dollars (USD), including:

  • USD $7 million upon signing;
  • USD $3 million upon receiving Marketing Authorisation approvals in Belgium (already received) and France (expected shortly); and
  • USD $7 million upon receiving first reimbursed sales in France, Germany, Italy and Spain;
  • The remaining USD $37.5 million on achievement of certain sales based milestones.

Additionally MVP will receive a gross margin on product sold to Mundipharma and royalties based on net sales.

The agreement brings together two companies in a strategic collaboration that leverages their individual strengths, combining Mundipharma’s extensive and sustained experience in pain management globally, as well as its strong commercial capabilities, which will complement MVP’s expertise in manufacturing and emergency medical solutions.

Commenting on the alliance, MVP CEO Mr. John Sharman said, “Mundipharma shares our vision for Penthrox® and is committed to the development of Penthrox in Europe. Moreover, Mundipharma has the reach and financial capacity to drive sales much harder and faster than we could do with our own resources. Their role extends beyond simply marketing the product, as Mundipharma will play an active role in the further development of Penthrox for existing and new clinical applications”.

Kate Hurtig, Head of Pain at Mundipharma International, added, “Mundipharma has a proud heritage in pain management and continually strives to advance new therapeutics in this space. With this alliance we are excited to expand our portfolio into the field of emergency pain relief and we look forward to quickly advancing the European development and commercialisation of Penthrox to maximise its success. We are delighted about the opportunity to work with Medical Developments International and the prospect for growth that this collaboration brings.”

-Ends-

About Penthrox ®

Penthrox® (low dose methoxyflurane) is a non-narcotic self-inhaled analgesic for the emergency relief of moderate to severe pain associated with trauma and associated pain, bridging patients from acute pain to stabilised analgesia. Penthrox® is currently registered and marketed in 10 countries around the world, including Australia, South Africa and New Zealand. Elsewhere, it has already been or is in the process of being submitted to regulatory agencies in Hong Kong, Iran, Israel, Malaysia, Mexico, Russia, Saudi Arabia, Singapore and Taiwan.

About Mundipharma

The Mundipharma network of independent associated companies consists of privately owned companies and joint ventures covering the world's pharmaceutical markets. The Mundipharma network has a presence in 51 countries with more than 7,800 employees across the world. These companies are committed to bringing to patients the benefits of pioneering treatment options in the core therapy areas of pain management, oncology, respiratory and inflammatory conditions. Through innovation, design and acquisition, the Mundipharma network of independent associated companies delivers important treatments to meet the most pressing needs of patients, healthcare professionals and health systems worldwide.

For further information please visit: www.mundipharma.com

About Medical Developments International Ltd

MVP is an Australian company listed on the Australian Stock Exchange (ASX: MVP) delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, a fast acting trauma and emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

More about MVP at www.medicaldev.com

Contact information

For further information please contact:
Bily Kuo, Communications Manager
Mundipharma International
bily.kuo@mundipharma.co.uk
T: +44 (0) 1223 397 118
or
John Sharman, Chief Executive Officer
Medical Developments International Ltd
jsharman@medicaldev.com
T: +61 (3) 9547 1888
or
Rebecca Power
Weber Shandwick
E RPower@webershandwick.com
T 44 (0) 207 067 0866

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Zonoville Investments Limited Announces Agreement on Acquisition of RUSAL Shares19.2.2018 18:19Pressemelding

Zonoville Investments Limited, a consortium of investors led by Renova Group and Access Industries, announced today that it had reached an agreement with Onexim Group to purchase its 6% stake in the United Company RUSAL Plc. Following completion of the purchase, Zonoville Investments Limited and its associate SUAL Partners Limited will hold, in aggregate, approximately a 26.5% interest in United Company RUSAL Plc. About Renova Renova Group of companies (www.renova.ru) is a major private Russian business group which owns and manages assets in metallurgy, mining, chemical, construction, transport, energy, telecommunications, high-tech engineering, public utilities, medicine and financial sectors in Russia and abroad (CIS, Switzerland, Italy, South Africa and the United States of America). Renova’s largest assets include its interests in UC Rusal, T Plus Group, OCTO Telematics and Swiss-based technology concerns Schmolz+Bickenbach, OC Oerlikon, and Sulzer. About Access Industries Founded

The Digital Health Technology Show: The Leading Show for Healthcare Innovation Comes to London19.2.2018 18:05Pressemelding

Medical innovation will take centre stage for 2018, at the largest wearables and disruptive health technology event in the world, with never before-seen devices and applications and a raft of industry-leading speakers. The Digital Health Technology Show returns to London on the 13th & 14th March 2018 at London’s Excel, gathering together more than 6,000 attendees and over 100 exhibitors. The 2018 Conference programme boasts three tracks, with over 100 hours of content programmed. Attendees can choose to attend talks on the Digital Health Disrupt Stage – covering global innovation in healthcare, the Leadership Theatre – where senior healthcare figures in the UK will discuss and debate the challenges ahead, or the Patient Engagement Stage – delivering insights into how technology is being used in the real world. There will also be demonstrations of the latest medical innovations on the Innovation Stage, which will also host a start up competition – The Health Innovation Award. Over 200 s

World Patient Safety Summit is Sold Out But Space is Available at the Breakout Sessions, Held the Day after the World Summit, at the Royal Society in London19.2.2018 13:00Pressemelding

The latest advances in vaccine safety, reducing unnecessary C-sections and person & patient engagement will be among the varied breakout sessions offered the day after the 6th Annual World Patient Safety, Science & Technology Summit in London by the Patient Safety Movement Foundation. The breakout sessions will convene on Sunday, February 25, 2018 at the prestigious Royal Society, the independent scientific academy of the United Kingdom and the Commonwealth, dedicated to promoting excellence in science. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180219005119/en/ Limited Space available to participate with experts at the 6th Annual World Patient Safety, Science & Technology Summit Break Out Sessions at the Royal Society in London (Photo: Business Wire) The breakout sessions are full-day working meetings structured for shared learning on existing Actionable Patient Safety Solutions (APSS) – collaborative, evidence-based pro

Tampere Attracts AV Productions with a New Incentive19.2.2018 12:41Pressemelding

One of the City of Tampere’s strategic goals is to be an international meeting place for creativity and innovation. The development of the experience economy is an essential focus of the city’s business policy. The incentive system is being used to attract more local, national and international productions to the Tampere region. The goal is to promote the development of the industry and to increase the number of jobs and the turnover of commercial productions in Tampere. Through the incentive system, an audiovisual production may recover some of the costs it has spent on wages and service purchases in the Tampere region. A production meeting the incentive criteria may be refunded 10–15 per cent of the accepted costs accrued in the region. Professional productions that utilise the Tampere region as their location or use expertise from the area may apply for the incentive. Thanks to the growing number of productions, Tampere will become more visible in films and TV shows, which will add

Tempo Grows Revenue by 38% in 2017 to $17.9 Million19.2.2018 11:14Pressemelding

Tempo, creator of efficiency-enhancing project management software solutions for Atlassian’s Jira platform, announced strong results for its 2017 fiscal year ending December 31, 2017. “2017 marks another productive and successful year for Tempo, with December our highest grossing month ever and sales across our product range exceeding expectations,” commented Agust Einarsson, CEO, “The completion of our new cloud infrastructure and successful migration of our entire customer base to Amazon Web Services (AWS) marks a strategic milestone, empowering Tempo with a more scalable underlying platform and enabling us to deploy products to customers faster.” Highlights for 2017 include: Revenue grew 38% year-over-year to US$17.9 million Almost 2,000 new customers were acquired Launched our new cloud infrastructure Expanded product footprint beyond the Atlassian environment with Tempo for Slack North American operations continued to grow More than 120 partners worldwide Celebrated our 10-year an

Morrow Sodali Announces Appointment of David Shammai as Corporate Governance Director - Cross Border19.2.2018 10:05Pressemelding

Morrow Sodali today announced that David Shammai has joined the firm as Corporate Governance Director - Cross Border. David joins from APG Asset Management, the Dutch pension fund manager, where in his role as senior corporate governance specialist he was involved in voting, policy, and engagement. Based in the London office, David will focus on the firm’s growing corporate governance activities across its European offices. Together with Morrow Sodali’s expanding team of corporate governance professionals, David will work to further develop the firm’s governance services – ranging from benchmarking and assessments of governance practice to board advisory on engagement with investors. “At Morrow Sodali we recognise that today many of our clients face growing needs for an in-depth and meaningful dialogue with their investors on a broadening range of topics. Having David onboard - from one of the world’s largest fiduciary asset managers - demonstrates our reinforced commitment to helping